Treatment of Lyme Disease in Acrodermatitis Chronica Atrophicans
Acrodermatitis chronica atrophicans (ACA) is a recognised clinical presentation of Lyme disease that requires a specific, guideline-supported treatment approach. The structured regimen for this scenario is available below.
Clinical Scenario
This protocol applies to patients with Lyme disease who present with acrodermatitis chronica atrophicans. The presence of ACA defines the specific management pathway addressed here.
Treatment Approach
Current evidence supports the use of oral antibiotic therapy in this setting. The complete regimen — including the choice of agent, duration, and full clinical algorithm — is available in the structured protocol below.
References
- In patients with acrodermatitis chronica atrophicans, we suggest oral antibiotic therapy for 21–28 days over shorter durations (weak recommendation, low-quality evidence).